Judge offers early win for Arbutus as Moderna vaccine patent spat heats up

04 Apr 2024
endpts.com
VaccinePatent InfringementmRNA
A Delaware federal judge has sided with Arbutus’ interpretation of three patent claim terms in its case against Moderna, giving the biotech a small win in a drawn-out patent dispute.
Arbutus and Genevant filed suit against Moderna in 2022, alleging the company’s historic mRNA vaccine used lipid nanoparticle (LNP) technology developed and patented by Arbutus. While plaintiffs agreed that the Covid-19 pandemic would have been “immeasurably worse” without the widespread availability of Moderna’s vaccine, they argued that the achievement was made possible by Arbutus’ discoveries around LNPs.
Judge offers early win for Arbutus as Moderna vaccine patent spat heats up
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.